Wealth Awesome
TSX closed
Loading markets…
PARTNER SPOTLIGHT
CIBC Investor's Edge

Trade ETFs with $0 commission

Buy and sell over 200 ETFs to build your portfolio, commission-free.¹

  • ✓Over 200 eligible ETFs, commission-free when you trade online
  • ✓Screeners and tools to find ETFs that fit your goals
  • ✓Any account type, backed by the CIBC Digital Banking Guarantee

¹Online trades in ETFs on the Eligible ETF List; hold at least one business day. ETF fund fees still apply. Conditions apply.

Stocks

argenx’s $1.15B Unnatural Products Deal: What Investors Should Know

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:ARGX.US

Follow ARGX

Photos provided by Pexels

A November 10 headline asked whether argenx shares already reflect the value of its announced US$1.15 billion acquisition.

The headline followed November 9 reports that argenx had agreed to acquire Unnatural Products. The deal would add a peptide discovery engine and broaden the company’s immunology capabilities. The available headlines do not provide further deal terms.

Investor takeaway: The acquisition prompted the “fully priced” question. The supplied figures show a recent share price of US$960.04 and a 17.32% gain over one month.

argenx NV ADR

ARGX.US

Full stock page →

ARGX.US

argenx NV ADR

Source:WealthAwesomeWealthAwesome
↑ $139.41 (16.99%)
120 day period
$802.17$930.54$1058.90May 27Aug 21Nov 13

Market cap

$60.37B

P/E

33.3x

52W high

$1072.75

52W low

$661.85

1W change

+3.54%

Beta

-0.06

Analyst Price Targets

Based on 24 analysts covering ARGX · as of Nov 16, 2026

📈

Wall Street analysts forecast ARGX stock price to rise 19.2% over the next 12 months.

Consensus

Buy

4.46 / 5.00

Avg. Target

C$1144.74

+19.2% Upside

Previously C$1147.35 on Nov 2, 2026

Current Price

C$960.04

Last close

Analyst Breakdown (24 analysts)

Strong Buy 14
Buy 7
Hold 3
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on ARGX's historical volatility

HistoricalForecast68%95%
C$447.74C$683.52C$919.29C$1155.06C$1390.84C$1626.61TodayJul 10Sep 14Nov 13Dec 26Feb 8Mar 23

30-Day Vol

51.5%

Annualized

90-Day Vol

46.7%

Annualized

Trend (90d)

-32.8%

Annualized drift

90d Mean

C$853.79

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$923.23C$773.05 – C$1102.59
60 trading daysC$887.83C$690.70 – C$1141.23
90 trading daysC$853.79C$627.78 – C$1161.18

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

US$1.15 billion deal; US$960.04 last close

The US$1.15 billion figure is the value cited in the acquisition headlines. Separately, argenx’s last close was US$960.04. Shares were up 17.32% over one month and 14.29% year to date.

Bull case

The acquisition would add a peptide discovery engine and broaden argenx’s immunology capabilities, giving the deal a stated strategic rationale.

Bear case

The November 10 headline raises a valuation question. Shares had gained 17.32% over the preceding month, according to the supplied performance figures.

The acquisition prompted the valuation question

On November 9, headlines reported that argenx would acquire Unnatural Products for up to US$1.15 billion. Another described the deal as a way to add a peptide discovery engine and broaden the company’s immunology capabilities.

The next day, a headline questioned whether argenx shares already looked fully priced despite the acquisition. The available headlines do not state the payment structure or expected closing date. Investors can follow ARGX.US on the argenx stock page.

Shares had gained 17.32% over one month

argenx’s last close was US$960.04. The supplied figures show a 2.17% decline over one day, a 3.54% gain over one week, a 17.32% gain over one month and a 14.29% gain year to date.

Latest volume was 5,333 shares, compared with a 20-day average of 420,013. The reported volume ratio was 0.54x. The share price was within its supplied 52-week range of US$661.85 to US$1,072.75, at 73% of that range. These figures provide trading context but do not show how much of the recent price movement was related to the acquisition.

Deal execution is the next event to follow

The acquisition’s stated aim is to add peptide discovery capabilities and broaden argenx’s immunology work. Investors can watch for updates on the transaction’s progress and how the acquired capabilities fit that aim.

The available company-news headlines cover the announcement and its rationale, but provide no completion timeline or further implementation details. For company and share information, see the argenx listing page.

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: November 16, 2026
Last Updated: November 16, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26